艾曲泊帕二线治疗成人原发免疫性血小板减少症以实现停药持续缓解的II期多中心前瞻性研究
该II期多中心前瞻性研究纳入51例成人新诊断或持续性原发免疫性血小板减少症(ITP)患者,接受艾曲泊帕治疗24周,主要终点为停药持续缓解(SROT)。13/51(25%)达到SROT,开始减量者中13/34(38%)达到SROT。基线IL-10、IL-4、TNF-α和骨桥蛋白较高为应答的负性预测因素。
要点
- 艾曲泊帕二线治疗成人ITP,25%患者可实现停药持续缓解。
- 开始减量患者中38%可实现停药持续缓解。
- 基线IL-10、IL-4、TNF-α和骨桥蛋白较高负性预测应答。
核心结论
- 艾曲泊帕治疗可使部分成人ITP患者实现停药持续缓解。
- 部分免疫学参数可预测艾曲泊帕应答。
研究设计与样本
- II期多中心前瞻性研究,纳入51例≥18岁新诊断或持续性ITP患者。
- 艾曲泊帕治疗24周,主要终点为停药持续缓解(SROT),观察期6个月。
主要发现
- 13/51(25%)治疗患者达到SROT。
- 开始减量的34例患者中13例(38%)达到SROT。
- 基线TPO水平与第24周应答及SROT均无关。
临床怎么用
- 艾曲泊帕二线治疗成人ITP时,可尝试减量停药以实现停药持续缓解。
- 基线IL-10、IL-4、TNF-α和骨桥蛋白较高者应答可能性较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Up to 30% immune thrombocytopenia (ITP) patients achieve a sustained remission off-treatment (SROT) after discontinuation of thrombopoietin receptor agonists (TPO-RAs). Factors predictive of response are lacking. Patients aged ≥18 years with newly diagnosed or persistent ITP were treated with eltrombopag for 24 weeks. Primary end-point was SROT: the proportion of responders that were able to taper and discontinue eltrombopag maintaining the response during a period of observation (PO) of six months. Secondary end-points included the association between some immunological parameters (TPO serum levels, cytokines and lymphocyte subsets) and response. Fifty-one patients were evaluable. Primary end-point was achieved in 13/51 (25%) treated patients and 13/34 (38%) patients who started the tapering. Baseline TPO levels were not associated with response at week 24 nor with SROT. Higher baseline levels of IL-10, IL-4, TNF-α and osteopontin were negative factors predictive of response (P = 0·001, 0·008, 0·02 and 0·03 respectively). This study confirms that SROT is feasible for a proportion of ITP patients treated with eltrombopag. Some biological parameters were predictive of response.
引用
- Lucchini E, Palandri F, Volpetti S, et al. Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. Br J Haematol. 2021. PMID: 33618438. doi:10.1111/bjh.17334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。